Jay A Berzofsky

US Patent:

6592872, Jul 15, 2003

Filed:

Sep 15, 1997

Appl. No.:

08/937276

Inventors:

Kurt Klimpel - San Diego CA
Theresa J. Goletz - Kensington MD
Naveen Arora - Delhi, IN
Stephen H. Leppla - Bethesda MD
Jay A. Berzofsky - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3907

US Classification:

42419711, 4241831, 4241921, 4242361, 4242461, 4241841, 4241931, 42419511, 514 2, 514885, 530350, 530323, 530403, 530402, 530806, 530825

Abstract:

The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.

US Patent:

6685944, Feb 3, 2004

Filed:

Oct 19, 2001

Appl. No.:

09/763260

Inventors:

Jay A. Berzofsky - Bethesda MD
C. David Pendleton - Bethesda MD
Stephen M. Feinstone - Washington DC
Marian E. Major - Alexandria VA
Pablo Sarobe - Pamplona, ES

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3929

US Classification:

4241891, 435 5, 435 724, 4353201, 4242281, 514 15, 530327, 530350, 536 2372

Abstract:

The present invention provides 1) an isolated peptide having the amino acid sequence DLMGYIPAV, (SEQ ID NO: 1); 2) an isolated HCV core polypeptide comprising an LâA substitution at amino acid position 139; 3) an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2; and 4) a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. The present invention further provides methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

US Patent:

6749856, Jun 15, 2004

Filed:

Jun 12, 2000

Appl. No.:

09/508552

Inventors:

Jay A. Berzofsky - Bethesda MD
Igor M. Belyakov - Gaithersburg MD
Michael A. Derby - Germantown MD
Brian L. Kelsall - Washington DC
Warren Strober - Bethesda MD

Assignee:

The United States of America, as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 3921

US Classification:

4241881, 4242081, 424434, 424435, 424436, 530324, 530826

Abstract:

The invention provides methods for induction of an antigen-specific, mucosal cytotoxic T lymphocyte response useful in preventing and treating infections with pathogens that gain entry via a mucosal surface.

US Patent:

7074410, Jul 11, 2006

Filed:

Feb 2, 2004

Appl. No.:

10/770117

Inventors:

Jay A. Berzofsky - Bethesda MD, US
Stephen M. Feinstone - Washington DC, US
Marian E. Major - Alexandria VA, US
Pablo Sarobe - Pamplona, ES

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/29
C07H 21/00
C07H 21/04

US Classification:

4241891, 4241841, 4241851, 4241861, 4242051, 4242281, 536 2372

Abstract:

Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

US Patent:

7094405, Aug 22, 2006

Filed:

Dec 6, 1999

Appl. No.:

09/455076

Inventors:

Jay A. Berzofsky - Bethesda MD, US
Jeffrey D. Ahlers - Kensington MD, US
C. David Pendleton - Bethesda MD, US
Peter Nara - Frederick MD, US
Mutsunori Shirai - Kagawa, JP

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/21

US Classification:

4241881, 4242081, 4241921, 530324, 530325, 530326

Abstract:

Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the Dclass I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.

US Patent:

7097965, Aug 29, 2006

Filed:

May 27, 2003

Appl. No.:

10/446890

Inventors:

Kurt Klimpel - San Diego CA, US
Theresa J. Goletz - Kensington MD, US
Naveen Arora - Delhi, IN
Stephen H. Leppla - Bethesda MD, US
Jay A. Berzofsky - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12N 5/00
C07K 19/00

US Classification:

435 2, 435375, 530403, 530806, 4241931, 4241921, 42419711

Abstract:

The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary toxin protective antigen and the antigen, which is bound to a binary toxin protective antigen binding protein. In one embodiment the vaccine is comprised of an anthrax protective antigen and the antigen bound to anthrax protective antigen binding protein. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.

US Patent:

7189513, Mar 13, 2007

Filed:

Mar 22, 2002

Appl. No.:

10/472661

Inventors:

Samir N. Khleif - Silver Spring MD, US
Jay A. Berzofsky - Bethesda MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

C12Q 1/68

US Classification:

435 6, 435 691, 435325

Abstract:

This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.

US Patent:

7341726, Mar 11, 2008

Filed:

May 5, 2006

Appl. No.:

11/429670

Inventors:

Jay A. Berzofsky - Bethesda MD, US
Pablo Sarobe - Pamplona, ES
Stephen M. Feinstone - Washington DC, US
Marian E. Major - Alexandria VA, US

Assignee:

The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/29
C07H 21/04
C12N 15/00

US Classification:

4241891, 4241841, 4241851, 4241861, 4242041, 4242281, 4353201, 536 2372

Abstract:

Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.